The pathophysiology of endometriosis is still unknown and treatment options remain controversial. Searches focus on angiogenesis, stem cells, immunologic and inflammatory factors. This study investigated the effects of etanercept and cabergoline on ovaries, ectopic, and eutopic endometrium in an endometriosis rat model. This randomized, placebo-controlled, blinded study included 50 rats, Co(control), Sh(Sham), Cb(cabergoline), E(etanercept), and E + Cb(etanercept + cabergoline) groups. After surgical induction of endometriosis, 2^nd operation was performed for endometriotic volume and AMH level. After 15 days of treatment: AMH level, flow cytometry, implant volume, histologic scores, immunohistochemical staining of ectopic, eutopic endometrium, and ovary were evaluated at 3^rd operation. All groups had significantly reduced volume, TNF-α, VEGF, and CD 146/PDGF-Rβ staining of endometriotic implants comparing to the Sh group (p < 0.05).TNF-α staining of eutopic endometrium in all treatment groups was similar to Sh and Co groups (p > 0.05). E and E + Cb groups significantly decreased TNF-α staining in the ovary comparing to Sh, Co, and Cb groups (p < 0.05). All treatment groups had significantly higher AFC compared to the Sh group. CD25⁺ Cells’ median percentage was significantly increased in the E + Cb group compared to Co, Sh, Cb, and E group. E + Cb group had a significantly higher CD5⁺ Cells’ level than the Co group (p = 0.035). In conclusion; Etanercept and/or Cabergoline decreased volume, TNF-α, VEGF, and CD 146/PDGF-Rβ staining of the ectopic endometrial implant. E and E + Cb treatment decreased TNF-α levels in the ovary. E + Cb also increased peripheral blood CD25⁺ & CD5⁺ Cell’s.

子宫内膜异位症的病理生理学仍然未知，治疗方案仍存在争议。搜索集中于血管生成、干细胞、免疫和炎症因子。本研究在子宫内膜异位症大鼠模型中调查了依那西普和卡麦角林对卵巢、异位和在位子宫内膜的影响。这项随机、安慰剂对照、盲法研究包括 50 只大鼠、Co（对照）、Sh（假）、Cb（卡麦角林）、E（依那西普）和 E + Cb（依那西普 + 卡麦角林）组。手术诱导子宫内膜异位症后，对子宫内膜异位症的体积和AMH水平进行了第二次手术^{。治疗 15 天后：在第3}天评估 AMH 水平、流式细胞术、植入体积、组织学评分、异位、在位子宫内膜和卵巢的免疫组织化学染色手术。与 Sh 组相比，所有组的子宫内膜异位症植入物的体积、TNF-α、VEGF 和 CD 146/PDGF-Rβ 染色显着减少（p < 0.05）。所有治疗组的在位子宫内膜的 TNF-α 染色与 Sh 相似和 Co 组 (p > 0.05)。与 Sh、Co 和 Cb 组相比，E 和 E + Cb 组显着降低了卵巢中的 TNF-α 染色（p < 0.05）。与 Sh 组相比，所有治疗组的 AFC 显着升高。与 Co、Sh、Cb 和 E 组相比，E + Cb 组的CD25 ^{+细胞百分比中值显着增加。}E+Cb组CD5 ^{+显着升高}细胞水平高于 Co 组 (p = 0.035)。综上所述; 依那西普和/或卡麦角林减少异位子宫内膜植入物的体积、TNF-α、VEGF 和 CD 146/PDGF-Rβ 染色。E 和 E + Cb 处理降低了卵巢中的 TNF-α 水平。E + Cb 也增加外周血 CD25 ⁺ & CD5 ⁺细胞的。